IDH3A and central nervous system cancer: High-grade gliomas (adult-type diffuse WHO grade 3 and 4 gliomas) account for up to 85% of all new cases of malignant primary brain tumors diagnosed every year, with an incidence of approximately 5/100,000 person years in Europe and North America (1). Of these, approximately 70% are either “glioblastomas, isocitrate dehydrogenase (IDH)-wildtype” or “astrocytoma, IDH-mutant, grade 4” (2).